ArticleCanadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
Cannabis use in patients with insomnia and sleep disorders: Retrospective chart review.
Article in Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Psychotherapeutic, pharmacological and other active interventions from the NICE guideline for post-traumatic stress disorder with sleep disorder: systematic review and meta-analysis.BMC psychiatry · 2025Pooled it
- Sleep quality of adult recreational cannabis users: a systematic review of literature.Trends in psychiatry and psychotherapy · 2025Pooled it
- Cannabis use and sleep outcomes among National Guard and Reserve soldiers.Psychological services · 2026Article
- The effects of tetrahydrocannabinol and cannabidiol on sleep in cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Nighttime Sleep Symptoms and Sleep-Relevant Medication Documentation Among Adults Receiving Buprenorphine for Opioid Use Disorder.Substance abuse and rehabilitation · 2026Article
- A comparative network analysis to explore cancer patient experiences with cannabis.Frontiers in psychiatry · 2026Article
- Canadian real-world evidence: observational 24-week outcomes for health care practitioner authorized cannabis.Canadian journal of pain = Revue canadienne de la douleur · 2026Article
- Article
- UK Medical Cannabis Registry: A clinical outcomes analysis for insomnia.PLOS mental health · 2025Article
- Systematic literature review of the impact of psychiatric pharmacists.The mental health clinician · 2024Review
- UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia.Brain and behavior · 2024Article
- Association Between Cannabis Use and Subjective Cognitive Decline: Findings from the Behavioral Risk Factor Surveillance System (BRFSS).Current Alzheimer research · 2024Article
- Development of cannabis use disorder in medical cannabis users: A 9-month follow-up of a randomized clinical trial testing effects of medical cannabis card ownership.Frontiers in psychiatry · 2023Article
- Characterization of the Use and Perceptions of Cannabis for Mental Health in Older Canadians: A Cross-Sectional Analysis.Sage open agingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Medical cannabis has been increasingly used in Canada after being sanctioned by Health Canada in 2001. Insomnia and sleep disorders are among the most common conditions for which patients report using cannabis. Current research shows cannabis may have a beneficial effect in sleep disorders and may improve patient-reported sleep scores. Methods: A retrospective chart review was conducted at Hybrid Pharm community pharmacy in Ottawa, Ontario, and included patients who were interested in, or already using, medical cannabis for sleep disorders. A qualitative, exploratory approach was taken to evaluate the descriptive efficacy and safety of medical cannabis when prescribed for insomnia or comorbid conditions. The comprehensive data collection also involved investigating the impact of cannabis on other medication used for insomnia. Results: A total of 38 patients were identified as having adequate follow-up documentation to assess the impact of medical cannabis. At time of data collection, 15 patients (39%) were able to reduce or completely discontinue a prescription medication indicated for sleep. On follow-up, 27 patients (71%) reported a subjective improvement in their sleep or related condition. Only 8 patients (21%) reported any adverse effects from medical cannabis use, and these were manageable and did not require discontinuation of cannabis. Conclusion: This study highlights the importance of a pharmacist's role in the management of cannabis-based therapy, including ongoing supportive care, follow-up and medication management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.